Beovu Eye Injection Lawsuit 2026: Vision Loss Claims, Who Qualifies & How to File

If you received Beovu eye injections for wet age-related macular degeneration and then suffered retinal vasculitis or retinal vascular occlusion, you may have a legal claim against the manufacturer, Novartis. Beovu has not been recalled and no large settlement exists, so cases are judged individually — but the documented safety record gives injured patients a basis to seek legal review.

For more plain-language explainers on money, insurance, and legal topics, see the Problem Solved channel.

Key Facts

  • The FDA approved Beovu (brolucizumab) on October 7, 2019, to treat wet AMD. It is given by injection directly into the eye.
  • In February 2020, the American Society of Retina Specialists reported 14 cases of retinal vasculitis in Beovu patients — 11 of them occlusive. Within a month the count rose to 25 cases, 21 involving occlusion.
  • Novartis said roughly 46,000 Beovu injections were administered in the first four months after approval, and more than 57,700 vials had shipped by February 2020.
  • In June 2020, the FDA approved an updated Beovu label warning of retinal vasculitis and retinal vascular occlusion.
  • A 2026 analysis of FDA adverse-event reports found brolucizumab accounted for 311 of 554 retinal vasculitis reports (56.1%) across eye-injection drugs from 2020 to 2025.

What Beovu Is, and What "Wet AMD" Means

Wet age-related macular degeneration — "wet AMD" — is an eye disease in which abnormal blood vessels grow beneath the retina and leak fluid or blood, damaging the macula, the small central area of the retina responsible for sharp, straight-ahead vision. Beovu is an anti-VEGF drug: "anti-VEGF" means it blocks vascular endothelial growth factor, a protein that drives the growth of those abnormal vessels. The idea is elegant — starve the leaking vessels, preserve central vision. Many patients welcomed Beovu because its dosing schedule promised fewer clinic visits than older drugs. What nobody expected was the particular injury that began surfacing within months: inflammation of the retina's own blood vessels.

The 2020 Safety Reports That Started Everything

Four months after approval, the American Society of Retina Specialists (ASRS) — the professional body for retinal surgeons — sent its members an urgent update: 14 Beovu patients had developed retinal vasculitis, inflammation of the vascular branches of the arteries in the retina. Eleven of the 14 had occlusive retinal vasculitis, meaning the inflammation had blocked blood vessels in the eye, a condition that can cause permanent vision loss. A month later the numbers had climbed to 25 cases of retinal vasculitis, 21 involving occlusion. Retinal vasculitis announced itself with blurred vision, floaters, dark spots, distorted images, and dulled color perception — symptoms that demand emergency eye care. Against that backdrop, retinal specialists began abandoning the drug: in an August 2020 editorial in the American Journal of Ophthalmology, two prominent physicians wrote that they had "stopped using brolucizumab because of the associated inflammation," noting that patients had safer alternatives without this risk.

The June 2020 Label Change

The lawsuits filed since then turn on one central question: did Novartis warn doctors and patients soon enough? When Beovu launched, its label mentioned common eye side effects such as blurred vision, light sensitivity, eye pain, and blood vessel inflammation — but not the specific threat of occlusive retinal vasculitis. After the ASRS reports and an FDA safety review, the label was updated in June 2020 to disclose that "retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported," instructing patients to report any change in vision without delay. Plaintiffs' lawyers argue that people treated before that warning were put at risk without informed consent. To date there has been no voluntary or mandatory recall of Beovu, and no large mass-tort settlement — litigation is still developing, with cases proceeding individually rather than in a consolidated multidistrict proceeding.

Who May Qualify for a Claim

A potential Beovu claim generally rests on three pillars. First, documented Beovu injections — ideally before the June 2020 label change, when the specific warning did not exist. Second, a qualifying injury: retinal vasculitis, retinal vascular occlusion, severe intraocular inflammation, retinal detachment, or significant vision loss following the injections. Third, medical records connecting the two — ophthalmology notes, optical coherence tomography (OCT) scans, and vision measurements taken before and after treatment. People who received Beovu after the warning was added face a steeper path, since the defense will argue the risk was disclosed. Deadlines also matter: every state sets its own statute of limitations for product-liability claims, typically measured from when the injury was discovered or should have been discovered.

How a Claim Works and What It Costs to Start

Because no consolidated proceeding exists, Beovu cases are filed as individual lawsuits. Most drug-injury firms handle these on a contingency basis — meaning no upfront legal fee, with the firm paid a percentage only if the case succeeds. A first consultation is typically free and confidential. If you are considering a claim, gather your injection records (dates and which eye was treated), every ophthalmologist's report mentioning vasculitis or occlusion, and any documentation of vision changes, missed work, or additional treatment such as corrective surgery. For the broader playbook, see our guides to pharmaceutical injury claims and Ozempic vision-loss litigation, plus our lawyer-selection guide. Do not delay: records get harder to assemble with time, and filing deadlines are strict. And keep seeing your eye doctor — protecting your remaining vision comes before any legal strategy.

Who Benefits From This — and Who Does Not

Who benefits:

  • Wet AMD patients who suffered retinal vasculitis or retinal vascular occlusion after Beovu injections — How: the documented safety record gives injured patients a basis to seek legal review: in February 2020 the American Society of Retina Specialists reported 14 cases of retinal vasculitis, 11 of them occlusive, rising within a month to 25 cases, 21 involving occlusion
  • Patients with injection and diagnosis records — How: the June 2020 label change warning of retinal vasculitis and retinal vascular occlusion, plus the 2026 analysis finding brolucizumab in 311 of 554 retinal vasculitis reports (56.1%) across eye-injection drugs from 2020 to 2025, frame the records that matter
  • Patients prepared for an individual case — How: Beovu has not been recalled and no large settlement exists, so cases are judged individually rather than through a class program

Who does not benefit:

  • Anyone expecting a recall or a large settlement — neither exists for Beovu: the drug was FDA-approved on October 7, 2019 and remains on the market with the updated June 2020 label warning
  • Patients without vision complications after injections — the claims in this guide turn on retinal vasculitis or retinal vascular occlusion after Beovu injections for wet AMD — an injection alone is not the claim
  • Anyone expecting a class action or MDL — there is no class program here: cases are judged individually, so each patient's injection history and diagnosis carry the claim

Related reading: Stryker Hip Lawsuit 2026: the $1.43 Billion Settlement, Who Missed It & Who Can Still File

Frequently Asked Questions

Has Beovu been recalled?

No. To date there has been no voluntary or mandatory recall of Beovu. The FDA instead approved an updated label in June 2020 warning of retinal vasculitis and retinal vascular occlusion, and the drug remains on the market.

What is the key legal issue in the Beovu lawsuits?

Whether Novartis adequately and promptly warned doctors and patients about the risk of occlusive retinal vasculitis. Plaintiffs' central claim is that patients treated before the June 2020 label change never received that specific warning.

Is there a Beovu class action or MDL?

Not yet. There has been no large class action or federal multidistrict litigation for Beovu; cases are proceeding as individual lawsuits while the litigation develops. That can change, so check current status before filing.

What records strengthen a Beovu claim?

Injection records with dates and the treated eye, ophthalmology notes documenting vasculitis or occlusion, OCT imaging, vision measurements before and after treatment, and records of any follow-up care or surgery.

Who benefits most from the Beovu guide — and who does it not help?

It helps most wet AMD patients who suffered retinal vasculitis or retinal vascular occlusion after Beovu eye injections and who have injection and diagnosis records — the February 2020 safety reports and the June 2020 label warning give those cases their documented basis. It does not help patients without vision complications after injections, or anyone expecting a recall, a large settlement or a class action: none exists, and cases are judged individually.

How do I start a Beovu claim review?

Gather the records this guide identifies as strengthening a claim — your Beovu injection history and your retinal vasculitis or retinal vascular occlusion diagnosis — and note the timeline: FDA approval on October 7, 2019, the February 2020 safety reports, and the June 2020 label change. Then seek legal review of your individual case, since there is no class program to join.

This article provides general information about the Beovu litigation, not legal or medical advice. If you believe you were injured, consult a qualified drug-injury attorney and your eye doctor.

Watch on YouTube

Problem Solved on YouTube